Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
Louise Kostos, James P Buteau, Jing Xie, Anthony Cardin, Tim Akhurst, Ramin Alipour, Lewis Au, Joanna Chan, Kwang Chin, Brittany Emmerson, Luc Furic, Q. F. B. Rodríguez García, Anthony J Hamilton, Mohammad B. Haskali, Price Jackson, Raghava Kashyap, Grace Kong, Lisa MacFarlane, Declan G. Murphy, Belinda S. Parker, Aravind S. Ravi Kumar, Javad Saghebi, Yang Wang, Ben Tran, Arun Azad, Michael S. Hofman
Topics & Concepts
MedicineProstate cancerInterim analysisOncologyInternal medicineCancerInterimClinical trialProstateGynecologyPhases of clinical researchDiseasePhase (matter)ChemotherapyRadiation therapyProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Diagnosis and Treatment